Autoimmune Disorders
Sanofi gears up for approval of its BTK inhibitor, meets Phase III endpoint
Sanofi’s rilzabrutinib met the primary endpoint in the Phase III persistent or chronic immune thrombocytopenia trial.
Eliem Therapeutics agrees to acquire Tenet
Vertex joins pharma immunotherapy deal uptick with $4.9bn Alpine purchase
FDA grants approval for Alexion’s NMOSD treatment
Capstan secures $175m Series B funds for CAR-T therapy
Vicore licenses idiopathic pulmonary fibrosis therapy to Nippon in Japan
